KAN 201
Alternative Names: KAN-201Latest Information Update: 30 Aug 2023
At a glance
- Originator Anokion
- Class Antihyperglycaemics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Type 1 diabetes mellitus
Most Recent Events
- 26 Jun 2023 Preclinical trials in Type 1 diabetes mellitus in Switzerland (unspecified route) (Anokion pipeline, June 2023)